At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 183 enrolled

Drug / intervention

PA21 +4 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01521494

NCT01521494Phase 2Completed

Compare CT.gov

PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia

Kissei Pharmaceutical Co., Ltd.·interventional·Posted Jan 30, 2012·Updated Aug 23, 2018

In Brief

A Phase 2 clinical trial evaluating PA21 and Placebo for Chronic Kidney Disease Requiring Hemodialysis. Completed, enrolled 183 participants across 1 site.

Detailed Summary

To investigate dose-response efficacy and safety in hemodialysis patients with hyperphosphatemia.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsChronic Kidney Disease Requiring Hemodialysis

CountriesJapan

Collaborators--

Timeline

Phase 2CompletedFinished

201220132014201520162017201820192020202120222023202420252026

Enrollment StartJan 2012

First PostedJan 2012

Primary CompletionJul 2012

TodayJul 2026

First PostedJan 30, 2012

Enrollment StartJan 11, 2012

Primary CompletionJul 3, 2012

TodayJul 2, 2026

Enrollment to primary: 6 monthsPosted 14.4 years ago

Interventions

PA21drug

Placebodrug